Publications without Fulltext

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14288/3

Browse

Search Results

Now showing 1 - 10 of 14076
  • Placeholder
    Publication
    Nörolojik hastalıkların genetik yönü
    (İÜC Yayınevi İstanbul Üniversitesi, 2024-01-01) Everest,Elif;Turanlı,Eda Tahir;Siva, Aksel;Kızıltan, Meral;Saip, Sabahattin;Yeni, Seher Naz;Savrun, Feray Karaali; Başak, Ayşe Nazlı; School of Medicine
  • Placeholder
    Publication
    İlişkili Taraf İşlemleri ile Şirket Malvarlığının Azaltılmasını Engelleyen Hukuki Mekanizmalar
    (On İki Levha, 2023-01-01) Altay,Anlam;Ayoğlu,Tolga;Fülürya Yusufoğlu, Bilgin; Çolgar, Emek Toraman; Law School
  • Placeholder
    Publication
    Visualizing lipophagy as a new mechanism of the synthesis of sex steroids in human ovary and testis using immunofluorescence staining method
    (Springer Nature, 2024-01-01) Türksen, Kürşad; Öktem, Özgür; Esmaeilian, Yashar; Yusufoğlu, Sevgi; İltümür, Ece; Bildik, Gamze; School of Medicine; Graduate School of Health Sciences; Animal Laboratory
    Immunofluorescence, a transformative tool in cellular biology, is employed to dissect the intricate mechanisms of cholesterol trafficking in human reproductive tissues. Autophagy, a key player in cellular homeostasis, particularly lipophagy, emerges as a free cholesterol source for steroidogenesis. In this chapter, we describe a comprehensive immunofluorescence staining protocol, with details provided for the precise visualization of subcellular dynamics of mitochondria, lysosomes, and lipid droplets in ex vivo testicular tissue and primary luteal granulosa cell culture models, pivotal components in sex steroid biosynthesis. Here, we detail the culture, treatment, and immunofluorescence protocols, providing a comprehensive guide for researchers. The provided immunofluorescence toolkit serves as a valuable resource for researchers, paving way for advancements in human reproductive health to investigate the intricate interplay between autophagy, lipophagy, and cholesterol trafficking.
  • Placeholder
    Publication
    Manyetik rezonans görüntüleme sistemi bileşenleri
    (Dünya Tıp Kitabevi, 2024-01-01) Ertürk, Şükrü Mehmet;Gelal, Fazıl; Özmen, Evrim; School of Medicine
  • Placeholder
    Publication
    Mustafa Reşid Pasha
    (Brill, 2023-01-01) Fleet, Kate;Krämer, Gudrun;Matringe, Denis;Nawas, John;Stewart, Devin J.; Department of History; Köksal, Yonca; College of Social Sciences and Humanities
  • Placeholder
    Item
    Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
    (Taylor and Francis Ltd, 2023) 0000-0002-1273-1674; Bilici, Ahmet; Olmez, Omer Fatih; Kaplan, Muhammed Ali; Oksuzoglu, Berna; Sezer, Ahmet; Karadurmus, Nuri; Cubukcu, Erdem; Sendur, Mehmet Ali Nahit; Aksoy, Sercan; Erdem, Dilek; Basaran, Gul; Cakar, Burcu; Shbair, Abdallah T. M.; Arslan, Cagatay; Sumbul, Ahmet Taner; Sezgin Goksu, Sema; Karadag, Ibrahim; Cicin, Irfan; Gumus, Mahmut; Harputluoglu, Hakan; Demirci, Umut; N/A; Selçukbiricik, Fatih; Faculty Member; School of Medicine; 202015
    AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) patients in a real-life setting.MethodsA total of 1528 female HER2+ BC patients who received NCT plus H with or without P were included in this retrospective real-life study. Primary endpoint was pCR rate (ypT0/Tis ypN0). Clinicopathological characteristics, event-free survival (EFS) time, and relapse rates were evaluated with respect to HER2 blockade (NCT-H vs. NCT-HP) and pCR.ResultsOverall, 62.2% of patients received NCT-H and 37.8% received NCT-HP. NCT-HP was associated with a significantly higher pCR rate (66.4 vs. 56.8%, p < 0.001) and lower relapse (4.5 vs. 12.2%, p < 0.001) in comparison to NCT-H. Patients with pCR had a significantly lower relapse (5.6 vs. 14.9%, p < 0.001) and longer EFS time (mean(SE) 111.2(1.9) vs. 93.9(2.7) months, p < 0.001) compared to patients with non-pCR. Patients in the NCT-HP group were more likely to receive docetaxel (75.0 vs. 40.6%, p < 0.001), while those with pCR were more likely to receive paclitaxel (50.2 vs. 40.7%, p < 0.001) and NCT-HP (41.5 vs. 32.1%, p < 0.001). Hormone receptor status and breast conservation rates were similar in NCT-HP vs. NCT-H groups and in patients with vs. without pCR. Invasive ductal carcinoma (OR, 2.669, 95% CI 1.596 to 4.464, p < 0.001), lower histological grade of the tumor (OR, 4.052, 95% CI 2.446 to 6.713, p < 0.001 for grade 2 and OR, 3.496, 95% CI 2.020 to 6.053, p < 0.001 for grade 3), lower T stage (OR, 1.959, 95% CI 1.411 to 2.720, p < 0.001) and paclitaxel (vs. docetaxel, OR, 1.571, 95% CI 1.127 to 2.190, p = 0.008) significantly predicted the pCR.ConclusionsThis real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time.
  • Placeholder
    Item
    Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis
    (Turkiye Klinikleri, 2023) 0000-0002-1273-1674; Açikgöz, Özgür; Bilici, Ahmet; Tataroğlu Özyükseler, Deniz; Göktaş Aydin, Sabin; Rzazade, Rashad; Ölmez, Ömer Fatih; Başak Çağlar, Hale; N/A; Selçukbiricik, Fatih; Faculty Member; School of Medicine; 202015
    Background/aim: Oligometastatic disease for nonsmall cell lung cancer (NSCLC) patients is generally thought to represent a better prognosis with a quieter biology, limited number of disease sites and long-term disease control. In this study, we aimed to determine the efficacy of radical treatment options for patients with oligometastatic NSCLC. Materials and methods: This retrospective trial included totally 134 patients with oligometastatic NSCLC. The presence of oncodriver mutation, tumor stages and nodal status, the number of metastases and involved metastatic site, treatment of primary tumor and oligometastasis, response rate, overall survival (OS) and progression-free survival (PFS) were evaluated. Results: Of 134 patients 66.4% were defined as adenocarcinoma, 26.1% were squamous cell carcinoma and 7.5% of patients were in other histology. Based on the treatment of primary tumor, in 36 patients (26.9%) curative surgery has undergone, in addition, 19 (14.2%) patients were received chemotherapy, 73 (54.5%) were treated with chemoradiotherapy, while immunotherapy and targeted therapy were used in 1 (0.7%) and 2 (1.4%), respectively. The preferred treatment for oligometastatic lesions were SBRT in 72.4% of patients, surgery in 10.5%, and both SBRT and surgery in 17.1% of patients. At the median follow up of 31.3 months (range: 9.5–48.5), the median PFS and OS times were 17 and 24.4 months, respectively. Moreover, OS-2 after progression was also 7.2 months. Conclusion: Based on our real-life experience, we demonstrated a significant correlation between good response to first treatment and survival in oligometastatic disease, we also understand that local ablative treatment modalities prolong and also delay both OS and PFS in oligometastatic NSCLC patients OS-2. © TÜBİTAK.
  • Placeholder
    Item
    The effectiveness of online pain management education on the patient related barriers to cancer pain management: a randomized controlled trial
    (Elsevier Sci Ltd, 2023) 0000-0002-1273-1674; 0000-0002-9585-6332; Bilmic, Ezgi; N/A; N/A; Selçukbiricik, Fatih; Bağçivan, Gülcan; Faculty Member; Faculty Member; School of Medicine; School of Nursing; 202015; 261422
    Purpose: This study aimed to evaluate the effectiveness of an online individualized education program on patientrelated barriers to cancer pain management.Methods: In this parallel randomized controlled trial, 110 participants were assigned to the intervention or control group. Online individualized education was conducted as the intervention. Depending on participants' preferences, online education sessions were completed via Microsoft Teams, Zoom, or WhatsApp. The primary outcome is patient-related barriers to cancer pain management, and the secondary outcome is pain intensity. The Patient Information Form, the Edmonton Symptom Assessment Scale (ESAS), the Brief Pain Inventory (BPI), and the Barriers Questionnaire II (BQ-II) were used for data collection. The statistical effects of the intervention on the outcomes were modeled in repeated measures ANOVA test.Results: The results show that both the group (F = 11.316, p = 0.001) and time effects (F = 63.878, p < 0.001) individually have significant effects on the BQII total score. Also, there is a significant difference between groups regarding BQII total score regardless of time. The interaction between group and time is also significant (F = 127.764, p < 0.001) and substantially affects the BQII total score. Regarding pain intensity, the results show that the interaction between group and time is statistically significant for all pain categories (p < 0.05). In contrast, the group effect is not statistically significant for all pain categories (p > 0.05). Time effects are statistically significant for the "least" and "average" pain only (p < 0.05).Conclusion: The result of this study presents evidence that individualized online education of cancer patients positively impacts reducing patient-related barriers to pain management and pain intensity.
  • Placeholder
    Item
    Major and minor salivary gland cancers: a multicenter retrospective study
    (Wiley, 2023) 0000-0002-1273-1674; Hacioglu, Muhammet Bekir; Erdogan, Bulent; Bardakci, Murat; Algin, Efnan; Gulbagci, Burcu; Hacibekiroglu, Ilhan; Hamdard, Jamshid; Olmez, Omer Fatih; Akkus, Hadi; Oksuzoglu, Berna; Goksu, Sema Sezgin; Dae, Shute Ailia; Sumbul, Ahmet Taner; Ugrakli, Muzaffer; Karaagac, Mustafa; Sahin, Elif; Cabuk, Devrim; Ozer, Ozden; Yavuzsen, Tugba; Arikan, Rukiye; Kostek, Osman; Atci, Muhammed Mustafa; Sakin, Abdullah; Deligonul, Adem; Bayir, Duygu; Dincer, Murat; Unsal, Oktay; Yazici, Ozan; Zeynelgil, Esra; Gulmez, Ahmet; Harputluoglu, Hakan; Erol, Cihan; Sendur, Mehmet Ali Nahit; Aytekin, Aydin; Akagunduz, Baran; Oner, Irem; Er, Ozlem; Oztosun, Bugra; Gumus, Mahmut; Biricik, Fatih Selcuk; Aykan, Musa Baris; Karadurmus, Nuri; Degerli, Ezgi; Demirci, Nebi Serkan; Turkmen, Esma; Sakalar, Teoman; Secmeler, Saban; Tanriverdi, Ozgur; Alkan, Ali; Kemal, Yasemin; Cil, Ibrahim; Unal, Caglar; Iriagac, Yakup; Alan, Ozkan; Balli, Sevinc; Urun, Yuksel; Ozcan, Erkan; Turhal, Nazim Serdar; Cicin, Irfan; N/A; Selçukbiricik, Fatih; Faculty Member; School of Medicine; 202015
    BackgroundMost of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data. MethodsA total of 37 medical oncology clinics from different regions of Turkey participated in this retrospective-multicenter study. The analyzed data included clinical and demographical features, primary treatment, metastasis localizations, and treatments and includes certain pathologic features. ResultsThe study included data from a total of 443 SGCs. 56.7% was in major salivary glands and 43.3% was in minor salivary glands. Distant metastasis in the major SGCs was statistically significantly more common than in the minor SGCs, locoregional recurrence was statistically significantly more common in the minor SGCs than in the major SGCs (p = 0.003). ConclusionsEpidemiological information, metastasis and recurrence patterns, treatment modalities, and survival analysis of the patients over 20 years of follow-up are presented.
  • Placeholder
    Item
    Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    (Future Medicine Ltd, 2023) 0000-0002-1273-1674; Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gumusay, Ozge; Bayram, Ertugrul; Demirel, Burcin Cakan; Acar, Omer; Aksoy, Sercan; Baytemur, Naziyet Kose; Sahin, Elif; Cabuk, Devrim; Basaran, Gul; Paydas, Semra; Yaren, Arzu; Guven, Deniz Can; Erdogan, Atike Pinar; Demirci, Umut; Yasar, Alper; Bayoglu, Ibrahim Vedat; Hizal, Mutlu; Gulbagci, Burcu; Paksoy, Nail; Davarci, Sena Ece; Yilmaz, Funda; Dogan, Ozlem; Orhan, Sibel Oyucu; Kayikcioglu, Erkan; Aytac, Ali; Keskinkilic, Merve; Mocan, Eda Eylemer; Unal, Olcun Umit; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; Uluc, Basak Oyan; Ozcelik, Melike; Hacibekiroglu, Ilhan; Aydiner, Adnan; Demir, Hacer; Oksuzoglu, Berna; Cilbir, Ebru; Cubukcu, Erdem; Cetin, Bulent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yildirim, Nilgun; Alkan, Ali; Aksoy, Asude; Karakas, Yusuf; Ozkanli, Gulhan; Duman, Berna Bozkurt; Aydin, Dincer; Dulgar, Ozgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tugba; Aykan, Musa Baris; Inal, Ali; Iriagac, Yakup; Kalkan, Nurhan Onal; Keser, Murat; Sakalar, Teoman; Menekse, Serkan; Kut, Engin; Bilgin, Burak; Karaoglanoglu, Muge; Sunar, Veli; Ozdemir, Ozlem; Turhal, Nazim Serdar; Karadurmus, Nuri; Yalcin, Bulent; Sendur, Mehmet Ali Nahit; N/A; Selçukbiricik, Fatih; Faculty Member; School of Medicine; 202015
    Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.